Patents News & Analysis
3 articles
Market Mood
Circle (USDC) Acquires 1,000 IBM Blockchain Patents on July 27
On July 27, Circle, the issuer of USDC, acquired over 1,000 blockchain patents from IBM. This purchase makes Circle the largest holder of blockchain patents in the U.S. Previously, IBM held 790 U.S. blockchain patents, more than any American company. Circle aims to leverage this intellectual property across its services, including the USDC and Circle Payments Network, enhancing its offering in internet finance. This acquisition could influence investment in blockchain and digital finance by reinforcing Circle's competitive position in the market.
Read More: Circle (USDC) Acquires 1,000 IBM Blockchain Patents on July 27
Tesla (TSLA) Revives UK Lawsuit Over 5G Patent License Terms
Tesla (TSLA) successfully revived a lawsuit against U.S. firm InterDigital regarding a 5G patent license ahead of its vehicle launch in the UK. The High Court had ruled in 2024 against Tesla’s bid for a determination of fair, reasonable, and non-discriminatory (FRAND) terms to use certain patents. However, the UK Supreme Court overruled that decision, stating patent owners remain obligated to license under FRAND terms even when part of a patent pool. This ruling could impact patent licensing agreements for Tesla’s upcoming 5G vehicles in Britain and affects the legal landscape for patent use in the automotive sector.
Read More: Tesla (TSLA) Revives UK Lawsuit Over 5G Patent License Terms
US Supreme Court Supports Generic Drugmaker in Patent Case
The US Supreme Court upheld a decision favoring a generic drug manufacturer in a patent dispute involving 'skinny labels.' This ruling allows the sale of generic drugs that reference only certain indications of a patented drug, impacting the pharmaceutical industry. The decision is seen as significant in creating competition among drug manufacturers, potentially lowering prices. The outcome may influence market dynamics for both brand-name and generic drug companies, although specific companies and financial metrics were not disclosed.
Read More: US Supreme Court Supports Generic Drugmaker in Patent Case